The global contrast media injectors market size was estimated at USD 882.1 million in 2016. Technological advancements and increasing demand for minimally invasive surgeries are some of the major factors contributing to the market growth.
Technological advancements in the field of contrast media injectors, including IT-enabled solutions for syringeless, dual-head, and automated injectors, have brought about incremental changes in medical imaging. Syringeless injectors are more user-friendly, efficient, minimize contrast agent wastage, and provide contrast enhancement during imaging. For instance, in November 2016, Bracco Group launched a new syringeless injector CT Exprès 3D Contrast Media Delivery System in the U.S. This system provides several advantages, such as doing away with the need to fill and clean syringes, user-friendliness, and high efficiency.
Minimally invasive surgical procedures provide various advantages, such as smaller incisions, rapid wound healing, shorter hospital stays, less pain, and minor surgical wounds. Minimally invasive surgical procedures with contrast media injectors deliver high quality real-time imaging of the surgical site, and ensure that surgeons are treating the appropriate area. Thus, adoption of these products for minimally invasive surgeries is rising gradually, and this is expected to fuel growth.
Increase in prevalence of several chronic diseases, such as cancer, as well as cardiac, neurological, and orthopedic diseases, is expected to boost the market. According to American Cancer Society, around 1,688,780 new cancer cases are estimated to be diagnosed in 2017 in the U.S. Furthermore, according to CDC, 28.4 million adults were diagnosed with heart disease in the U.S. in 2015. Thus, there is growing demand for advanced products for diagnosis and treatment of chronic diseases, which is projected to drive growth.
Frequent product recalls are expected to hamper market growth. Product recalls have adverse effects on manufacturers’ businesses and reputation. They are also likely to affect customer loyalty to the manufacturers’ other products. In addition, recalls also question the efficiency of new products, thereby delaying their adoption by surgeons. For instance, in September 2013, FDA announced Class 2 Device Recall of MEDRAD Stellant CT Injector System with Certegra due to an issue with the software design. Also, in June 2016, Bayer Healthcare initiated the recall of MEDRAD MRXerion MR Injection System. Product recalls such as these negatively impact the mindset of customers, following which the product has to be discontinued.
In 2016, the CT injector systems segment was the largest revenue-generating segment of the market due to widespread application of these systems in cancer surgery, neurosurgery, cardiovascular surgery, and spinal procedures. In addition, high adoption of minimally invasive surgeries is expected to boost the market.
Also, the rising prevalence of chronic diseases, including cancer, neurological disorders, and arthritis, is expected to propel demand for this product segment. According to WHO, cancer is the second largest cause of death, and around 14.0 million new cases of cancer were diagnosed worldwide in 2012.
The MRI injector systems segment is expected to exhibit the highest growth over the study period owing to technological advancements, such as 3D isotropic imaging, high efficiency in tumor detection, higher quality visualization, and exquisite quality imaging. For instance, in November 2016, Ulrich GmbH & Co. KG announced the launch of its Max 2M and Max 3 innovative syringeless MRI injectors that provide more flexibility, accuracy, and require less time.
Manufacturers are focusing on the launch of innovative products to cater to unmet requirements of radiologists and surgeons. Innovative technologies, such as IT-enabled solutions for duel-head, syringeless, and automated injectors, provide high accuracy, efficacy, and image quality during disease diagnosis and surgery.
In 2016, the single head injectors segment accounted for the largest revenue share of the contrast media injectors market because it is most widely used for angiography, CT, and MRI. In addition, the low price of these products as compared to other systems is expected to drive demand in emerging economies, such as China, India, and Brazil. In addition, launch of new products is expected to boost this segment. For instance, in February 2016, Guerbet received FDA approval for the OptiOne Single-Head Contrast Delivery System, a CT contrast media injector for injection of radiopaque contrast media during CT scan.
Syringeless injectors segment is expected to grow with the highest CAGR during the forecast period owing to its advantages, such as user-friendliness, high efficiency, and minimum wastage of contrast media. Several leading players are focusing on development and launching of syringeless injectors, which is projected to drive the growth of the segment.
Availability of well-established healthcare infrastructure and high healthcare expenditure in developed countries, including the U.S., Japan, France, Germany, and the UK, is expected to boost the market. According to Centers for Medicare & Medicaid Services, U.S. healthcare expenditure was around USD 3.2 trillion in 2015 and accounted for approximately 17.8% of the gross domestic product. These factors are expected to support market growth.
The radiology segment held the largest share in the market because it is primary for diagnosis of various diseases, including heart conditions, breast cancer, colon cancer, broken bones, gastrointestinal conditions, and blood clots. In addition, this segment is projected to grow at a lucrative rate owing to rise in demand for noninvasive medical imaging techniques.
U.S., Japan, Germany, UK, and France are estimated to account for the maximum usage of contrast media injectors. Rise in the burden of several chronic diseases, growing investments by governments to improve healthcare infrastructure, and availability of expert radiologists in these countries is projected to contribute toward growth.
The interventional cardiology segment is projected to grow at the fastest rate during the forecast period owing to rise in prevalence of cardiac diseases, including arrhythmia, heart valve problems, stroke, and heart attack. Rise in prevalence of cardiac diseases has led to increase in demand for interventional cardiac surgery for diagnosis and treatment.
Technological advancements have also boosted the growth of the segment. For instance, in June 2012, Bayer HealthCare LLC launched new angiography injector, Mark 7 Arterion Injection System for angiography procedures. Also, escalating popularity of these products in emerging economies such as China, South Africa, India, Brazil, and Mexico is expected to boost the growth.
Hospitals held the highest market share owing to increasing admissions of patients suffering from cancer, neurological disorders, and cardiovascular diseases. According to CDC, in 2014, around 1,150 thousand patient suffering with heart disease including ischemic visited emergency department of hospital in the U.S.
Hospitals are primary users of the contrast media injectors because of its wide range of applications in radiology, interventional radiology, and interventional cardiology. Thus, this segment dominated the market in 2016, owing to the high patient turnaround and frequent readmissions. Furthermore, increasing focus on development of healthcare infrastructure in developing countries in the Asia Pacific and African region is expected to propel growth of the segment.
Diagnostic centers segment is expected to witness the significant growth during the forecast period owing to increasing cognizance about chronic diseases including cancer, neurological diseases, and neurodegenerative disorders. Growing awareness among people results in increased demand for CT and MRI procedures that are used for diagnosis, treatment planning, and prevention of such chronic disorders.
North America dominated the market with the largest revenue share because of the highly developed healthcare facilities. Also, accessibility to expert radiologist and surgeons in this region have fueled growth. Europe region held the significant revenue share due to local presence of several leading companies, such as Bracco Group; Guerbet Group; Bayer HealthCare LLC; ulrich GmbH & Co. KG; and Medtron AG.
Furthermore, the availability of advanced IT-enabled solutions for data management, that provide data to analyze imaging optimization, workflow efficiencies, and patient safety. For instance, Bayer HealthCare LLC offers the Radimetrics Enterprise Platform which can be integrated with Medrad MRXperion MR Injection System.
Asia Pacific region is estimated to show highest CAGR during the forecast period owing to developing healthcare infrastructure in Asian countries including China, India, and Indonesia. Furthermore, the growing prevalence of some chronic diseases, such as cancer, orthopedic diseases, epilepsy, and Alzheimer's disease, is projected drive growth.
Several big corporations, such as Bracco Group; Guerbet Group; Medtron AG; Bayer HealthCare LLC; ulrich GmbH & Co. KG; Nemoto Kyorindo Co., Ltd.; GE Healthcare; VIVID IMAGING; Sino Medical-Device Technology Co., Ltd.; and APOLLO RT Co. Ltd., share the market with medium - and small-sized vendors. They provide a broad range of advanced devices through their strong supply and distribution channels worldwide.
Leading players are involved in new product launch, mergers & acquisitions, strategic collaborations, and regional expansions to gain the maximum revenue share in the sector. Mergers & acquisitions help companies to expand their businesses and regional presence. For instance, In November 2015, Guerbet acquired contrast media & delivery systems business of Mallinckrodt (UK) to expand their medical imaging business globally primarily in Europe and America.
However, intense rivalry amongst vendors has led to high pressure on pricing strategies. Moreover, high cost of systems and adverse effects of contrast agents including iodinated contrast, barium, gadolinium, and microbubble agents, is likely to limit their adoption by healthcare professionals.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million & CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, UK, France, Italy, Spain, Germany, Japan, India, China, Brazil, Mexico, South Africa, Saudi Arabia
Revenue forecast, company share, competitive landscape, growth factors, and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global contrast media injectors market on the basis of product, type, application, end use, and region:
Product Outlook (Revenue, USD Million; 2014 - 2025)
CT injector systems
MRI injector systems
Cardiovascular/angiography injector systems
Injector Type Outlook (Revenue, USD Million; 2014 - 2025)
Application Outlook (Revenue, USD Million; 2014 - 2025)
End Use Outlook (Revenue, USD Million; 2014 - 2025)
Ambulatory surgery centers
Regional Outlook (Revenue, USD Million; 2014 - 2025)
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.